Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 3/20 | 0.33 |
| ▸ | KDR known ✓ | P35968 | 3/20 | 0.32 |
| ▸ | BTK known ✓ | Q06187 | 3/20 | 0.32 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.32 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.32 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.32 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.32 |
| ▸ | INSR known ✓ | P06213 | 1/20 | 0.32 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.32 |
| ▸ | IGF1R known ✓ | P08069 | 1/20 | 0.32 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.32 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.32 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.32 |
| ▸ | JAK3 known ✓ | P52333 | 1/20 | 0.32 |
| ▸ | ITK known ✓ | Q08881 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 3/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946599 | 0.93 | PRKCQ (0.35) | PRKCQAURKAAURKBALKCSNK2A2 | |
| Sulfuric Acid SCHEMBL1944366 | 0.93 | PRKCQ (0.35) | PRKCQAURKAAURKBALKCSNK2A2 | |
| SCHEMBL1942477 | 0.91 | PRKCQ (0.37) | PRKCQAURKAAURKBALKCSNK2A2 | |
| Acetic Acid SCHEMBL1946734 | 0.88 | AURKA (0.37) | PRKCQAURKAAURKBALKCSNK2A2 | |
| SCHEMBL1942904 | 0.87 | CSNK2A2 (0.36) | PRKCQAURKAAURKBALKCSNK2A2 | |
| Benzoic Acid SCHEMBL1945412 | 0.87 | AURKA (0.39) | PRKCQAURKAAURKBALKCSNK2A2 | |
| Maleic Acid SCHEMBL1944864 | 0.87 | AURKA (0.35) | PRKCQAURKAAURKBALKCSNK2A2 | |
| Fumaric Acid SCHEMBL1944776 | 0.87 | AURKA (0.35) | PRKCQAURKAAURKBALKCSNK2A2 | |
| SCHEMBL1942360 | 0.86 | CSNK2A2 (0.36) | PRKCQAURKAAURKBALKCSNK2A2 | |
| Citric Acid SCHEMBL1945466 | 0.84 | AURKA (0.34) | PRKCQAURKAAURKBALKCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| EP-2507227-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068898-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | PIK3CD 192/4885KDR 2942/4885BTK 248/4885 |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | PIK3CD 192/4885KDR 2942/4885BTK 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.